Skip to content

Eur Neuropsychopharmacol

ISSN 0924-977x; 1873-7862;

4 papers in the library · 529 citations · publishing 2016-2026

Papers

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.

Eur Neuropsychopharmacol May 20, 2016 Anna Rickli, Olivier D. Moning, Marius C. Hoener et al. 374 citations

The study compares the receptor interaction profiles of novel psychoactive tryptamines to those of classic hallucinogens. It examines how these substances bind to and activate various serotonin receptors, which are key to their psychoactive effects. The findings indicate that many novel tryptamines have similar receptor activity to classic hallucinogens, but some show distinct profiles that may lead to different subjective effects or risks. This research helps understand the pharmacological basis of these emerging drugs and their potential harms.

DOI: 10.1016/j.euroneuro.2016.05.001

LSD modulates music-induced imagery via changes in parahippocampal connectivity.

Eur Neuropsychopharmacol April 12, 2016 Mendel Kaelen, Leor Roseman, Joshua Kahan et al. 143 citations

Lysergic acid diethylamide (LSD) alters how the brain processes music-induced mental imagery by changing connectivity in the parahippocampal region. This suggests that psychedelics can enhance or modify the subjective experience of music through specific neural mechanisms, potentially linking sensory perception and imagination.

DOI: 10.1016/j.euroneuro.2016.03.018 LSD Lysergic acid diethylamide Hallucinogens Psychedelics +19

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

Eur Neuropsychopharmacol November 7, 2025 Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al. 12 citations

A living systematic review with meta-analysis examined the efficacy, safety, and all-cause discontinuation of serotonergic psychedelics and MDMA for treating mental disorders. The review found that these substances show promise in reducing symptoms of conditions such as depression, anxiety, and post-traumatic stress disorder, with some evidence supporting their therapeutic potential. However, the authors note that the overall quality of evidence is limited by small sample sizes, short follow-up periods, and methodological concerns. Safety profiles varied, with most adverse events being mild to moderate, though serious adverse events were reported in some studies. The review emphasizes the need for larger, more rigorous trials to confirm these findings.

DOI: 10.1016/j.euroneuro.2025.09.011 Psychedelic therapy MDMA Therapy Psychedelic medicine Entheogenic therapy +12